1 Clinical performance validation of the STANDARD G6PD Test: A multi-

2 country pooled analysis

- Wondimagegn Adissu^{1,2}, Marcelo Brito^{3,4}, Eduardo Garbin⁵, Marcela Macedo⁵, Wuelton Monteiro^{3,4},
- 4 Sandip Mukherjee⁶, Jane Myburg⁷, Mohammad Shafiul Alam⁸, Germana Bancone^{9, 10}, Pooja Bansil¹¹,
- 5 Sampa Pal¹¹, Abhijit Sharma¹¹, Stephanie Zobrist¹¹, Andrew Bryan¹², Cindy S Chu^{9,10}, Santasabuj Das⁶,
- 6 Gonzalo J Domingo¹¹, Amanda Hann⁷, James Kublin^{12,13}, Marcus VG Lacerda^{3,4,14}, Mark Layton⁷,
- 7 Benedikt Ley¹⁵, Sean C Murphy^{16,17}, François Nosten^{9,10}, Dhélio Pereira^{5,18}, Ric N Price^{10,15}, Arunansu
- 8 Talukdar¹⁹, Daniel Yilma^{2,20}, Emily Gerth-Guyette^{11*}

9 **Affiliations:**

- 1. School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia
- 11 2. Clinical Trial Unit, Jimma University, Jimma, Ethiopia
- 3. Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas,
- 13 Brazil
- 14 4. Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil
- 5. Centro de Pesquisa Em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil
- 6. National Institute of Cholera and Enteric Diseases, Kolkata, India
- 17 7. Special Haematology Laboratory, Hammersmith Hospital, London, United Kingdom
- 8. Infectious Diseases Division, International Centre for Diarrheal Diseases Research, Bangladesh
- 19 (icddr,b), Mohakhali, Dhaka, Bangladesh
- 20 9. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of
- 21 Tropical Medicine, Mahidol University, P.O. Box 46, 68/31 Bann Tung Road, Mae Sot, 63110,
- Thailand.
- 23 10. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
- Oxford, Oxford, United Kingdom
- 25 11. Diagnostics, PATH, Seattle, Washington, United States of America
- 26 12. Departments of Laboratory Medicine and Microbiology, University of Washington School of
- 27 Medicine, Seattle, Washington, United States of America
- 28 13. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle,
- Washington, United States of America
- 30 14. Instituto Leônidas & Maria Deane (ILMD), Fiocruz, Manaus, Amazonas, Brazil
- 31 15. Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin
- 32 University, Darwin, Australia

33 16. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, 34 Washington, United States of America 17. Center for Emerging and Reemerging Infectious Diseases, University of Washington, Seattle, 35 36 Washington, United States of America 37 18. Universidade Federal de Rondônia (UNIR), Porto Velho, Rondônia, Brazil 38 19. Kolkata Medical College Hospital, India 39 20. Department of Internal Medicine, Jimma University, Jimma, Ethiopia 40 **Corresponding author:** Emily Gerth-Guyette

Abstract

- 43 Introduction: Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaguine and tafenoquine can be guided by point-of-care testing 44 45 for G6PD deficiency. 46 Methods and Findings: Data from similar clinical studies evaluating the performance of the STANDARDTM G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, 47 India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed 48 49 in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for 50 reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin 51 measurement. 52 The sensitivity of the STANDARDTM G6PD Test using the manufacturer thresholds for G6PD deficient 53 and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence 54 Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%– 55 85.4%) for females with intermediate activity between 30%-70%. Specificity was 98.1% (95% CI 56 97.6%-98.5%) and 92.8% (95% CI 91.6%-93.9%) for G6PD deficient individuals and intermediate 57 females, respectively. The majority (12/20) of G6PD intermediate females with false normal results had activity levels >60% on the reference assay. Negative predictive values for females with G6PD activity 58 59 >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Test sensitivity among 396 P. vivax 60 malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. In the study 61 population, a high proportion of those classified as G6PD deficient or intermediate resulted from true 62 normal cases. Despite this, the majority cases would receive the correct medication and no true G6PD 63 deficient cases would be treated inappropriately.
- 64 **Conclusions:** The STANDARD G6PD Test enables safe access to drugs which are contraindicated for
- 65 individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.
- 66 **Keywords:** G6PD enzyme activity, malaria, *Plasmodium vivax*, diagnostic performance

Introduction

67

68

69

70

7172

73

74

75

76 77

78

79

80

8182

83

8485

86

87

88

89

90

91

92

93 94

95

96 97

98

The glucose-6-phosphate dehydrogenase (G6PD) enzyme plays an essential role in the protection of red blood cells against damage from oxidative stress. This enzyme is one of the most polymorphic in the human genome, leading to many mutations resulting in the enzymopathy G6PD deficiency. G6PD deficiency is one of the most common human genetic disorder affecting an estimated 500 million people worldwide. The red blood cells of individuals with this condition have decreased G6PD enzyme activity and are more susceptible to hemolysis as a result of an oxidative challenge. Common oxidative challenges include from foods such as fava beans, infections such as SARS-CoV-2 infection^{3,4} and typhoid, and medications such as rasburicase⁵ and 8-aminoquinoline-based anti-malaria drugs used for radical cure treatment of *Plasmodium vivax* malaria (e.g., primaguine and tafenoquine).^{6,7} G6PD deficiency is also a strong predictor of pathologic neonatal jaundice and potential for life-threatening kernicterus in newborns.8-10 Until recently, diagnosis of G6PD deficiency has primarily relied on moderate to high complexity laboratory assays. In practice, the implementation of such tests has been challenging as described in recent publications from the College of American Pathologists. ^{11,12} More recently, point-of-care (POC) tests for G6PD deficiency are emerging, providing opportunities to expand testing to populations without access to laboratory-based assays. 13 Such tests are particularly important in the context of malaria case management, given the limited infrastructure in settings where malaria patients typically seek care. At a global level, the World Health Organization recommends G6PD testing prior to the administration of radical cure treatments for *P. vivax* malaria. However, among malaria-endemic countries, policies and practices related to G6PD testing and radical cure implementation vary significantly, based in part on the underlying epidemiology of G6PD deficiency as well as barriers to access and adoption.¹⁵ POC tests for G6PD deficiency include both qualitative rapid tests, as well as quantitative biosensor tests that provide numeric results of patients' G6PD activity levels. Two qualitative tests have shown promise under laboratory conditions, but have limitations in field conditions, including challenges with temperature correction and the inability to identify females with intermediate G6PD activity arising from a heterozygous $g6pd_{normal}/g6pd_{deficient}$ genotype. ^{16–18} The STANDARD G6PD Test (SD Biosensor, Republic of Korea) is a quantitative enzymatic colorimetric assay intended to aid in the detection of G6PD deficiency at the POC. The test measures G6PD enzyme activity normalized by hemoglobin (Hb) (U/g Hb) and total-hemoglobin concentration (g/dL) on 10 μl of capillary or venous blood samples. Results are provided within two minutes on a portable, handheld analyzer and used to classify individuals as G6PD normal, intermediate, or deficient according to the manufacturer's recommended thresholds.

99

100

101

102103

104

105

106107

108

109

110

111112

113

114

115

116

117118

119

120

121

122123

124

125

126

127

128

This classification can be used to inform clinical decision-making, particularly as it relates to priority applications, such as malaria case management. Cross-sectional diagnostic accuracy studies have been conducted in a wide range of settings and locations, to evaluate the performance of the STANDARD G6PD Test . 19-22 Pooling data from these studies allows for a robust diagnostic performance analysis across diverse populations representative of multiple contexts and use cases for POC G6PD testing. Our aim was to 1) present these data for the STANDARD G6PD Test, 2) explore how a common set of thresholds to classify G6PD deficient or intermediate individuals with POC testing can be applied across populations, and 3) consider the implications of the test performance on 8-aminoquinoline malaria treatment regimens. **Materials and Methods** Data were included from similar cross-sectional diagnostic accuracy studies conducted in seven countries: Bangladesh, ²¹ Brazil, ²⁰ Ethiopia (unpublished), India (unpublished), Thailand, ¹⁹ the United Kingdom, ²² and the United States 19,22 (Supplementary Table 1). Collectively, these studies span a varied range of underlying G6PD epidemiology and malaria incidence. The primary objective of all studies was to evaluate the performance of the STANDARD G6PD Test for its ability to identify G6PD normal, intermediate, and deficient individuals, and to evaluate the test's ability to measure hemoglobin concentration. The performance of the STANDARD G6PD Test on capillary and/or venous specimens was compared to G6PD reference values normalized by hemoglobin from venous specimens tested with a spectrophotometer. Only one study (Thailand) used frozen venous specimens. ¹⁹ The performance of the STANDARD G6PD Test in the measurement of hemoglobin concentration was also compared to a complete blood count from automated hematology analyzers where available, and/or to results from venous specimens on the HemoCue 201+ system. **Ethical considerations and study populations** All studies involving human subjects were reviewed by relevant ethics committees (Supplementary Table 1) and written informed consent to participate was obtained for all participants. Varying recruitment methods appropriate to each site were employed to ensure study populations that were both representative of intended use settings—including malaria-endemic settings and blood donation centers—as well as of G6PD activity levels across the dynamic range (Supplementary Table 1). **Testing** Supplementary Figure 1 summarizes the tests and overall workflow of the included studies.

129

130

131

132

133

134

135

136

137

138139

140

141

142143

144

145

146

147

148149

150

151

152

153154

155

156

157

158

Contrived specimen study

STANDARD G6PD Test. The STANDARD G6PD Test was performed in all studies on nonanticoagulated capillary and/or venous K₂EDTA whole blood as per the manufacturer's instructions. In addition to the analyzer, test components include disposable test strips (Test Devices), disposable blood transfer tubes (Ezi Tubes+), extraction buffer vials, and a lot-specific code chip used for calibration. For testing on capillary specimens, 10 µl of blood was collected via fingerprick using a disposable Ezi Tube+ and mixed with the extraction buffer. Next, a second, clean Ezi Tube+ was used to transfer 10 µl of the mixed specimen to the Test Device, which is inserted into the analyzer. When run on venous specimens, 10 μl of blood was transferred to the buffer solution using either a professional pipette^{20–22} or the Ezi Tube+ sample collector. 19,22 After two minutes, the test reports quantitative measurements of G6PD activity in U/g Hb and hemoglobin (g/dL). The manufacturer's recommended G6PD activity thresholds were applied to determine G6PD status based on the quantitative test result: 4.0 U/g Hb and 6.0 U/g Hb for G6PD deficient (<30% activity) and intermediate (<70% activity), respectively. Reference G6PD testing. In all studies, spectrophotometry was used as the reference assay on venous K₂EDTA whole blood, using a temperature-regulated instrument. Either the Pointe Scientific (Canton, MI, catalog number G7583) or the Trinity Biotech (Bray, Ireland) G6PD reagent kits were used. All G6PD activity results were normalized for hemoglobin concentration and are presented in U/g Hb. Hemoglobin measurement. Hemoglobin was measured according to the following methods: Complete blood count (CBC). In the Bangladesh, Brazil, Ethiopia, India, Thailand, and US (2021) studies in Pennsylvania and Washington, 19-22 total hemoglobin concentration (g/dL) was determined using a CBC on an automated hematology analyzer. This measurement served as the reference method for the measurement of Hb concentration and was used to normalize the reference assay for G6PD activity. • HemoCue 201+. With the exception of the Bangladesh and Thailand studies, the HemoCue Hb 201+ System was also performed on non-anticoagulated capillary blood and/or venous K₂EDTA blood as a comparative measure of hemoglobin concentration in g/dL according to the manufacturer instructions. For studies where CBC was not available, the HemoCue 201+ measurement was used to normalize the reference assay for G6PD activity. Malaria testing. In three studies, the malaria status of participants was assessed by the standard method at each site—either microscopy (Brazil) or rapid diagnostic test (Ethiopia and India).

159

160

161162

163

164

165

166

167

168169

170

171

172

173

174175

176

177

178

179

180181

182

183

184185

186 187

188

189

Lastly, data are also presented for a contrived specimen study²² that included a panel of 90 specimens spanning critical G6PD activity thresholds developed using heat abrogation and following a method adapted from the UK National External Quality Assurance Services G6PD scheme.²³ Five contrived specimens representing a broad hemoglobin concentration range were also developed using plasma-level adjustment. These 95 samples underwent blinded testing with the STANDARD G6PD Test and reference assay. **Statistical methods** Due to the observed inter-laboratory variability of the G6PD reference assay, 11,22 absolute G6PD values were normalized for each laboratory conducting the reference assay in each study. 24-26 Reference G6PD activity values were expressed as the percentage of each site's adjusted male median (AMM). For the majority of studies, the AMM was calculated from a subset of randomly selected males (n=36) with normal G6PD status as determined by each laboratory's reference range. These 36 males were subsequently excluded from the analytical population for the performance analysis. In the UK study, 39 males were used to calculate the AMM. In the Bangladesh study, the AMM was calculated from the median activity of all known G6PD normal participants. For the Thai study, the AMM was calculated as described in Domingo et al. (2013), ²⁷ wherein all males with reference G6PD activity \leq 10% of the male median were excluded, and a new median activity was determined and used to normalize the reference data. A Kruskal Wallis test was used to compare medians between groups. Next, categorical thresholds were used to classify G6PD deficient cases (males and females with < 30% activity), and females with intermediate activity (> 30% and \leq 70% activity). Using pooled data from across all included studies, receiver operating characteristic (ROC) curves were generated to assess the ability of the test to discriminate G6PD deficient males and females, G6PD intermediate females, and G6PD normal males and females. The pooled performance of the STANDARD G6PD Test against the spectrophotometric reference test for each specimen type was determined by calculating the test's sensitivity and specificity, and 95% confidence interval (CIs) to diagnose individuals G6PD status at the 30% and 70% thresholds. ²⁷ For the purposes of this analysis, G6PD deficient and intermediate results by the reference assay were considered as true "positive", and G6PD normal results were considered as true "negatives." Overall agreement between the STANDARD G6PD Test and reference assay in the classification of normal, intermediate, and deficient G6PD activity levels was calculated and Kappa coefficients were determined at the same thresholds. Agreement was assessed for the STANDARD G6PD Test's T-Hb measurement against the

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217218

219220

reference CBC assay results where available, using clinically-relevant thresholds for anemia established by the World Health Organization (WHO) (Supplementary Table 2).²⁸ All statistical analyses were performed using Stata® 15.0 (StataCorp, College Station, TX). To explore the implications of these results for malaria case management, the eligibility of the pooled study population for radical cure treatment regimens was considered. These eligibility criteria were based on the WHO recommendations regarding administration of primaquine for preventing relapse¹⁴ as well as the product label for tafenoquine (Supplementary Table 3). Across the study population, G6PD classification by the reference assay was compared to G6PD classification by the SD Biosensor test. Next, theoretical treatment eligibility among the study population was calculated based on the results of both the reference assay and the STANDARD G6PD Test, with the former considered as the gold standard and true discriminating test while the latter was considered as the test that would determine treatment status. Based on the concordance or discordance between methods, participants were considered as either correctly or incorrectly receiving or being excluded from the recommended treatment algorithm outcome. Results are presented separately for two different treatment algorithms: 1) primaquine only, and 2) tafenoquine and primaquine, with those who were considered ineligible for tafenoquine then considered for primaquine eligibility. No other treatment eligibility criteria (e.g., age, pregnancy, anemia status) were considered as part of the calculation. **Results** Data from 4,212 capillary specimens and 4,844 venous specimens were included in the analysis (Table 1). The overall population was split evenly between males and females. The majority of participants with available data had either no or mild anemia. A total of 550 patients with confirmed malaria were included in the analysis. **G6PD** activity distribution The site-specific AMMs are reported in Supplementary Table 4. Study-specific median G6PD values and interquartile ranges (IQRs) for all normal males in the analytical populations on both the reference assay and the STANDARD G6PD Test on capillary and venous specimens are presented in Figure 1 and Supplementary Table 5. On the reference assay, the G6PD median ranged from 6.8 U/g Hb to 11.9 U/g Hb, as compared to 6.7 U/g Hb to 11.3 U/g Hb on the STANDARD G6PD Test. Overall, the G6PD median of the STANDARD G6PD Test was within a 1.5 U/g Hb range, with the exception of one of the US studies. 19 No correlation was observed between the reference assay G6PD normal male median and that of the STANDARD G6PD test across studies (data not shown). In Brazil and India, the study

221

222

223

224

225

226

227

228

229

230

231

232

233

234235

236

237

238239

240

241

242

243

244

245

246247

248

249

250

251

252

population was recruited from those seeking care for malaria (Supplementary Table 1) and included a sufficient number of P. vivax cases among normal males. There was no significant difference in the AMM between malaria negative males and P. vivax positive males (Table 2). Among G6PD normal males, the median G6PD activity was significantly lower for P. vivax positive males compared to malaria negative males at the Kolkata, India, site, but not at the Porto Velho, Brazil, site. Based on the 30% and 70% activity thresholds, data were available for 266 G6PD deficient, 233 G6PD intermediate, and 4,520 G6PD normal specimens (Table 1). The pooled prevalence for G6PD deficient and intermediate cases in the capillary sample analytical population was 3.4% and 2.1%, respectively (Supplementary Table 6). The pooled prevalence for G6PD deficient and intermediate cases in the venous blood analytical population was 5.4% and 4.7%, respectively (Supplementary Table 6). Supplementary Figure 2 presents the distribution of G6PD activities in the study population according to the reference assay and the STANDARD G6PD Test for both males and females. Pooled clinical performance of the STANDARD G6PD Test for G6PD ROC curves (Supplementary Figure 3) and associated performance characteristics (Supplementary Table 7) show that the test performed well in detecting deficient individuals at the 30% activity threshold; the area under the curve (AUC) was 0.998 and 0.997 for capillary and venous specimens, respectively. At the 70% threshold for intermediate females, AUC was 0.909 for capillary and 0.954 for venous specimens. Table 3 summarizes the pooled diagnostic performance of the STANDARD G6PD Test for identifying G6PD deficient males and females, and females with intermediate G6PD activity, by specimen type. Overall, at the 30% threshold, the test had a sensitivity of 100% for both specimen types. The specificity was 96.7% (95% CI 96.1%-97.2%) for combined venous and contrived specimens and 98.1% (95% CI 97.6%–98.5%) for capillary specimens. For females with intermediate G6PD activity levels, the sensitivity was 77.0% on capillary specimens (95% CI 66.8%–85.4%), 86.6% on venous specimens excluding contrived (95% CI 80.6%–91.3%), and 89.0% on venous specimens including contrived (95% CI 85.4%–93.6%). Specificity was 92.8% for capillary specimens (95% CI 91.6%–93.9%), 94.9% for venous specimens without contrived (95% CI 93.3%–95.3%), and 93.9% for venous specimens including contrived (95% CI 92.8%-94.9%). Overall agreement was 94.8% for capillary and venous specimens, and 93.8% for venous and contrived specimens combined (Supplementary Table 6). All true deficient individuals were correctly identified by the STANDARD G6PD Test on both venous and capillary specimens and false normal results were only observed for females with intermediate G6PD activity (Figure 2; Table 4). On venous specimens, 10% (23/230) of intermediate females were misclassified as normal, compared to 25% (20/87) on capillary specimen (Table 4). However, the

253

254

255

256

257

258

259

260

261

262

263264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281282

283

majority (60%, 12/20) of these capillary discordant results were attributed to females with reference G6PD activity greater than 60% and only two samples had G6PD activities between 40 and 50%. (Supplementary Table 8; Table 5; Supplementary Figure 4). Negative predictive values for females with >60% reference activity were 99.6% and 99.5% for capillary and venous specimens (without contrived), respectively (Table 3; Table 5). In contrast, false positive results (particularly for intermediates) occurred in 6% (120/1934) of G6PD normal females who were misclassified as intermediate and 1.5% (34/2178) of G6PD normal males who were misclassified as deficient on capillary specimens. Pooled clinical performance of the STANDARD G6PD Test for G6PD among P. vivax confirmed cases Among participants with P. vivax malaria, on both capillary and venous specimens, sensitivity was 100% (95% CI 69.2%–100%) at the 30% threshold, with specificities of 99.0% (95% CI 97.4%–99.7%) and 97.7% (95% CI 95.6%–98.9%) for capillary and venous specimens, respectively (Table 3). However, it should be noted that this is based on a small number of deficient and intermediate cases (≤ 10) within this population. Pooled clinical performance of the STANDARD G6PD Test for hemoglobin Linear regression of the STANDARD G6PD Test's hemoglobin result as compared to the hemoglobin result on the reference CBC is shown in Supplementary Figure 5, by specimen type. R-squared correlation values are 0.73 and 0.77 for capillary and venous specimens, respectively. Supplementary Table 9 presents the agreement between the STANDARD G6PD Test's anemia classification on both capillary and venous specimens as compared to the CBC results. Overall percent agreement between methods was 90.3% (95% CI 89.0%–91.5%) for capillary specimens and 94.3% (95% CI 93.2%–95.2%) for venous specimens (excluding contrived). None of the participants with severe anemia (Hb < 7.0 g/dL for children 6-59 months of age or <8.0 g/dL for all other groups, n=44) were misclassified as non or mild anemia on either capillary or venous blood. **Implications for malaria treatment** The STANDARD G6PD test results on capillary specimens were used to calculate the implications of the test performance on eligibility to different radical cure treatment options. Figures 3A and 3B illustrate a scenario where only daily primaquine radical cure regimen is available to males and females with G6PD activity greater than 30%. Based on the results of the STANDARD G6PD test, 94.8% (3993/4212) of the participants, representing all G6PD normal and intermediate participants, would be eligible for standard daily primaquine according to WHO guidelines and correctly provided primaquine based on the

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313314

315

concordance between the reference and POC test. Conversely, 5.2% (219/4212) would be excluded from standard primaquine treatment (Figure 3B). No G6PD deficient participants would be prescribed primaquine, but 1.8% (76/4212) males and females with intermediate and normal G6PD activity would be excluded from the daily treatment regimen (Figure 3B; Supplementary Table 10). Figures 3C and 3D illustrate a scenario where both daily primaquine and single dose tafenoquine are available and tafenoquine is only available to males and females with G6PD activity greater than 70%. Based on the POC STANDARD G6PD test results 87.1% (3668/4212) of participants in the study population would be eligible for single dose radical cure (Figure 3C). One percent (43/4212) of the population with G6PD activity < 70% would receive tafenoquine. These were 23 males and 20 females with G6PD activity between 30-70%, with a median G6PD activity of 63%. This analysis found that 7.7% of the population (168 males and 157 females) had a STANDARD G6PD Test result between 4 and 6 U/g Hb and would be eligible for standard daily primaquine all of these had G6PD activity > 30%. Of these, 6.5 % of the total population (153 males and 120 females) had a reference G6PD activity >70% and could have been treated with tafenoquine (Figure 3D; Supplementary Table 10). **Discussion** In this paper, performance data for the STANDARD G6PD POC test for G6PD deficiency, was consolidated from multiple studies conducted on both capillary and venous specimens across seven countries, representing diverse settings and use cases for G6PD testing. **Application of universal thresholds** Performance estimates for the STANDARD G6PD Test were calculated by applying a single set of thresholds for G6PD deficiency and female intermediate activity in U/g Hb, as indicated by the manufacturer's instructions for use. For the reference assay, site-specific adjusted male medians were used to normalize results and establish 30% and 70% G6PD activity thresholds for defining deficient, intermediate, and normal cases. The male median G6PD activity on the POC test was more consistent across sites and specimen types—with the exception of one US site—in comparison to the reference assay, which showed greater site-to-site variability. Inter-site variability in the male median G6PD activity as defined by spectrophotometry has been described previously, ^{25,29} and is apparent even between sites testing the same specimens.²² Site-to-site reproducibility of the STANDARD G6PD Test conducted on commercially available controls also has decreased variability compared to the reference assay conducted on the same control reagents in the same laboratories.³⁰ However, it is important to note with respect to the medians and thresholds that the populations of the studies in this analysis largely comprised of adults and children over the age of two. Only one study (in the United Kingdom) included few

newborn samples. Using the STANDARD G6PD Test for newborn screening applications will require the use of higher G6PD threshold values to account for the higher G6PD activity among newborns. A recent study conducted in Thailand with the STANDARD G6PD Test on 307 cord blood samples showed good performance as long as the thresholds are adjusted to address the higher median G6PD activities in newborns. A recent report suggests that malaria infection may also result in increased G6PD activity when looking across all malaria in deficient and intermediate cases. However, in our analysis, there was no overall change in G6PD activity when comparing *P. vivax*-infected and uninfected males with normal G6PD activity. The male median G6PD value on the STANDARD G6PD test is statistically consistent across varied contexts and populations (aged two years and older), including in malaria-endemic settings, with the exception of newborns.

Clinical implications for malaria case management

316

317318

319

320

321322

323

324

325

326

327

328

329

330

331

332

333

334

335

336337

338339

340

341

342

343344

345

346

347

From a safety perspective, the sensitivity and negative predictive values of POC G6PD tests to identify G6PD deficient and intermediate cases are critical to minimize adverse reactions to drugs that are contraindicated in individuals with G6PD deficiency. This is particularly relevant for the test's use in malaria case management, as standard 14-day primaquine regimens used for the radical cure of P. vivax malaria are not recommended for G6PD deficient males and females, 37,38 and safety of higher dose regimens among G6PD intermediate females is also a concern.³⁹ Additionally, tafenoquine is the first drug to indicate a threshold G6PD activity (70%) on its label, above which data indicates that it is considered safe to prescribe for radical cure. ^{24,40} The calculations above suggest that the use of the STANDARD G6PD Test at the point of care reduce risk of drug related hemolysis and so facilitate appropriate provision of treatment, in line with WHO and global treatment guidelines. The STANDARD G6PD Test showed good performance both on capillary and venous samples for G6PD deficiency when applying the manufacturer's universal thresholds, and no G6PD deficient cases were misclassified as normal, which ensures G6PD deficient malaria patients will receive correct primaquine regimens. In fact, the STANDARD G6PD Test tends toward overestimation of G6PD deficiency at the deficient and intermediate thresholds as compared to the reference assay (Supplementary Table 6). The test's sensitivity decreased for females with intermediate activity. However, most of the false normal results were attributed to females with G6PD activities >60%, (and all of whom had activities >40%), which means that they are less likely to experience severe hemolysis as the potential for severe clinical outcomes increases among those with more severe deficiency (i.e., a low percent G6PD activity). The negative predictive values for females with G6PD reference activity >60% is good at 99.6% and 99.5%

348

349

350

351

352

353

354

355

356

357

358359

360

361

362

363

364

365

366

367

368369

370

371

372

373

374

375376

377

378

for both capillary and venous specimens, respectively. Among the almost 400 P. vivax cases included in this analysis, none of the deficient or intermediate cases were incorrectly classified as normal by the STANDARD G6PD Test. However, it should be noted that very few deficient and intermediate P. vivaxpositive cases were included in this sample. Of note, challenges associated with false normal G6PD results are not limited to POC tests. For context, a recent report from the College of American Pathologists (CAP) highlights challenges with the accurate diagnosis of specimens with intermediate G6PD activity in current reference clinical laboratory testing. 11 Among laboratories participating in the CAP proficiency testing, 12.5% of those conducting quantitative reference testing misclassified an intermediate specimen as normal, and 47.8% of those conducting qualitative testing misclassified it as normal. 11 These findings suggest that misclassifications of G6PD intermediate specimens are not unique to POC tests and that accurate classification of this group is a challenge in clinical laboratory testing. The specificity of a POC G6PD test is also important when considering performance, as such tests may result in valuable treatment options being withheld from individuals without contraindications. Because of the typically low prevalence of G6PD deficiency in many populations, any decrease in specificity will significantly reduce the positive predictive power of the test with a significant proportion of G6PD deficient and intermediate cases assigned by the POC test actually being G6PD normal individuals. This was observed in the data presented here, where false deficient or intermediate misclassifications on the STANDARD G6PD Test were more common than false normal results. Unpublished data from settings where the STANDARD G6PD test has been scaled up and used outside the context of closely monitored clinical studies indicates that the proportion of false deficient and intermediate cases appears to increase. In the context of malaria, an overestimation of G6PD deficiency may prompt concerns about unnecessarily restricting access to radical cure and higher levels of onward transmission and relapses. Implications for malaria programs and future research Results from this pooled performance analysis will inform future implementation and operational research efforts for this test. One recent usability study conducted among intended test users from three high malaria burden settings found that, with appropriate training, the test can be used in clinics managing malaria cases. 41 Recent studies also suggest that the incorporation of the test into P. vivax case management in Brazil and Laos is cost effective; however, factors such as clinic case burdens and G6PD deficiency prevalence are important considerations. ^{42,43} Together, these performance, usability, and costeffectiveness findings suggest that the STANDARD G6PD Test can be used in malaria endemic settings

379

380

381

382

383

384

385

386387

388

389

390

391

392

393

394

395

396

397

398

399

400

401 402

403

404

405 406

407

408

409

to support G6PD classification and significantly reduce the risk of drug induced hemolysis when prescribing primaguine or tafenoquine, as well as other drugs such as rasburicase.⁴⁴ However, the positive predictive power of the test among this population, where a significant proportion of individuals classified as G6PD deficient by the STANDARD test are in fact normal represents an operational challenge in settings where confirmatory testing cannot be conducted. As is common for many POC tests, confirmatory testing at a reference laboratory is also recommended if the test indicates a positive result for the disease status. 38,45 However, where a POC test has the most clinical utility, access to reference confirmatory testing is unlikely. One must consider how to appropriately counsel patients regarding the interpretation of their results. This and the above limitations in test sensitivity need to be considered in the overall risk benefit assessment of G6PD screening at the point of care, which should also take into consideration local G6PD prevalence and vivax epidemiology as well as other drug eligibility criteria. Additional safety and operational studies may be warranted. Future operational studies should investigate whether testing strategies that involve repeat testing over two or three consecutive occasions can improve confirmation of true G6PD deficient cases and the effective positive predictive value specially in settings with low prevalence in G6PD deficiency. Additionally, given the extremely high negative predictive value (100% for individuals >30% G6PD activity), exploring approaches to retain patients' G6PD test results could reduce the need for repeat testing for the vast majority of the population, potentially leading to significant cost savings. Finally, the feasibility of using the G6PD test at the community level where malaria careseeking often takes place will be critical to inform adoption strategies and scale. Limitations There are limitations to this analysis. The different studies contributing to this analysis were not originally designed as a multi-center clinical study, and this pooled analysis was not prospectively planned for all studies. However, the homogeneity in the designs of the included studies with regard to testing methods, data collection, and reporting allows for combining of the data. Importantly, all included studies used one of two compatible reference assays, the Trinity or the Point Scientific spectrophotometric reagent kits, which are based on the same chemistry. 46 Further, a systematic literature search was not employed to identify included studies. Lastly, our analysis includes fewer data generated from capillary specimens than venous specimens. However, studies that evaluated test performance on capillary specimens included several that were collected from POC settings in malaria endemic countries—Ethiopia, India, and Brazil—and specifically clinics managing malaria cases.

In summary, this pooled analysis supports the use of the STANDARD G6PD Test in near-patient settings where rapid turnaround screening for G6PD status is needed to inform patient care and has previously been unavailable. Operational and costing considerations should inform uptake of the test in specific settings.⁴⁷

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

Funding The Brazil, Ethiopia, India, Thailand, UK, and US studies were funded by the United Kingdom's Foreign, Commonwealth & Development Office (FCDO), grant number 204139 and, by the Bill & Melinda Gates Foundation [OPP1107113, OPP1054404 and OPP1164105]. The FCDO and Bill & Melinda Gates Foundation awards to PATH support the availability of point-of-care tests for G6PD deficiency. GB, CSC, and FN work at the Shoklo Malaria Research Unit, part of the Mahidol Oxford University Research Unit supported by the Wellcome Trust Mahidol Major Overseas Programme-Thailand Unit (Grant Number 220211). For the purpose of Open Access, the authors have applied a CC BY public copyright license to any author accepted manuscript version arising from this submission RNP and the Bangladesh study were funded by the Wellcome Trust (Senior Fellowship in Clinical Science, 200909), BL is funded by the Australian Department of Foreign Affairs and Trade, RNP is funded by the Bill & Melinda Gates Foundation (OPP1054404 and OPP1164105). MVGL and WMM are funded by Brazilian CNPq. Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License has been assigned to the Author Accepted Manuscript version that might arise from this submission. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions of FCDO or the Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Neither PATH, nor the co-authors have any financial interests in the commercial availability of any of the products discussed in this article. All authors read the journal's authorship statement. All authors have

read the journal's policy on conflict of interest and do not have a conflict of interest to disclose

437 **Tables**

438

Table 1. Summary of demographics.

	Bangladesh ^a	Brazil ^b	Ethiopia	India	UK°	US (2021) ^c	Contrived Specimens ^c	US (2019) ^d	Thailand ^d	Total n (%)
Specimen type	Fresh venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh venous K2EDTA	Fresh capillary and venous K2EDTA	Contrived venous	Fresh venous K2EDTA	Frozen venous K2EDTA	
Final Analytic population, n	108	1,736	1,015	951	167	623	95	174	150	5,019
Capillary Analytic population, n	N/A	1,693	1,009	889	N/A	621	N/A	N/A	N/A	4,212
Venous Analytic population, n	108	1,662	1,015	860	167	613	95	174	150	4,844
Sex, n (%)										
Female	81 (75.0)	948 (54.6)	476 (46.9)	345 (36.3)	87 (52.1)	309 (49.6)	90 (97.4)	73 (41.9)	108 (72.0)	2,517 (50.2)
Male	27 (25.0)	788 (45.4)	539 (53.1)	606 (63.7)	80 (47.9)	314 (50.4)	5 (5.3)	101 (58.1)	42 (28.0)	2,502 (49.8)
G6PD status, e n (%)			,							
Deficient < 30%	30 (27.8)	59 (3.4)	12 (1.2)	27 (2.8)	10 (6.0)	46 (7.4)	3 (3.2)	25 (14.4)	54 (36.0)	266 (5.3)
Intermediate 30%–70%	21 (19.4)	35 (2.0)	19 (1.8)	17 (1.8)	10 (6.0)	17 (2.7)	58 (61.1)	10 (5.7)	46 (30.7)	233 (4.6)
Normal >70%	57 (52.8)	1,642 (94.6)	984 (97.0)	907 (95.4)	147 (88.0)	560 (89.9)	34 (35.8)	139 (79.9)	50 (33.3)	4,520 (90.1)
Anemia status, f n (%)										
Non/mild	N/A	831 (47.9)	473 (46.6)	360 (37.9)	N/A	410 (65.8)	81 (85.3)	N/A	143 (95.3)	2,298 (45.8)

Moderate	N/A	83 (4.8)	1 (0.1)	91 (9.6)	N/A	23 (3.7)	11 (11.6)	N/A	7 (4.7)	216 (4.3)
Severe	N/A	10 (0.6)	0 (0)	30 (3.2)	N/A	1 (0.2)	3 (3.2)	N/A	0 (0)	44 (0.9)
Missing	108 (100.0)	812 (46.8)	541 (53.3)	470 (49.4)	167 (100.0)	189 (30.3)	0 (0)	174 (100.0)	0 (0)	2,461 (49.0)
Malaria result, ^g n (%)										
P. falciparum	N/A	12 (0.7)	27 (2.7)	29 (3.1)	N/A	N/A	N/A	N/A	N/A	68 (1.4)
P. vivax	N/A	199 (11.5)	0 (0.0)	242 (25.5)	N/A	N/A	N/A	N/A	N/A	441 (8.8)
P. falciparum/P. vivax	N/A	40 (2.3)	0 (0.0)	1 (0.1)	N/A	N/A	N/A	N/A	N/A	41 (0.8)
Negative	N/A	1,484 (85.5)	988 (97.3)	679 (71.4)	N/A	N/A	N/A	N/A	N/A	3,151 (62.8)

a. Data published within Alam et al., 2018.

b .Data published within Zobrist et al., 2021.

c. Data published within Pal et al., 2021.

d. Data published within Pal et al., 2019.

e. G6PD status as determined by the spectrophotometric G6PD reference test on venous specimens, based on the specified activity thresholds.

f. Anemia status as measured by CBC in accordance with published clinically relevant Hb concentration thresholds from WHO. The non- and mild anemia categories were combined based on the clinical significance of moderate or severe anemia diagnoses, consistent with the uses of other quantitative devices for the determination of Hb concentration at the point of care. Samples for which only HemoCue Hb 201+ results were available are not included in this summary. Additionally, samples from Bangladesh were not included because of the limitations in the granularity of the data available. g. Microscopy or rapid diagnostic test positive at recruitment.

450 Brazil, and Kolkata, India, sites, by *P. vivax* malaria status.

451

	Porto Velho, Brazil	Kolkata, India
AMM	N=36	N=36
AMM Normal Males Median 100% (95% CI)	8.9 (8.6–9.4)	8.56 (7.9–9.1)
AMM P. vivax Normal Males Median 100% (95% CI)	8.7 (7.8 – 9.4)	8.21 (7.6 – 9.3)
P value	0.35	0.24
All Normal Males (analytical population)	N=368 (all) N=114 (<i>P. vivax</i>)	N=582 (all) N=197 (<i>P. vivax</i>)
All Normal Males Median 100% (95% CI)	9.1 (8.3 – 10.1)	8.7 (7.7 – 10.0)
All <i>P. vivax</i> Normal Males Median 100% (95% CI)	8.9 (8.1 – 9.8)	8.2 (7.3 – 9.4)
P value	0.08	0.001

Table 3. Summary diagnostic performance of the STANDARD G6PD Test for identifying G6PD deficient males and females with intermediate G6PD activity, by specimen type, in all study participants and in *P. vivax* cases only.

Specimen type	Cases			Performance for G6PD deficient males and females		Performance for G6PD intermediate females (> 30, ≤ 70%)		3 x 3 overall percent agreement	Negative predictive value female > 60%
	Deficient cases, n	Intermediate cases, n	Normal cases, n	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	(95% CI)	(95% CI)
Capillary	143	79	3990	100.0 (97.5–100.0)	98.1 (97.6–98.5)	77.0 (66.8–85.4)	92.8 (91.6–93.9)	94.8 (94.1–95.5)	99.6 (99.1 – 99.8)
Venous (without contrived)	259	110	4380	100.0 (98.6–100.0)	97.6 (97.1–98.0)	86.6 (80.6–91.3)	94.4 (93.3–95.3)	94.8 (94.2–95.4)	99.5 (99.0 – 99.7)
Venous (with contrived)	262	152	4430	100.0 (98.6–100.0)	96.7 (96.1–97.2)	89.0 (85.4–93.6)	93.9 (92.8–94.9)	93.8 (93.1–94.5)	-
P. vivax-in	fected parti	cipants only							
Capillary	10	9	377	100.0 (69.2–100.0)	99.0 (97.4–99.7)	100.0 (39.8–100.0)	93.3 (86.7–97.3)	96.2 (93.8–97.9)	-
Venous	10	4	382	100.0 (69.2–100.0)	97.7 (95.6–98.9)	100.0 (39.8–100.0)	87.3 (79.2–93.0)	96.2 (93.8–97.9)	-

455

STANDARD G6PD Test Classification	Refer	Total									
Capillary: Male											
	Deficient	Nor	Total								
Deficient	134	30	164								
Normal	0	20	18	2018							
Total	134	204	48	2182							
Capillary: Female											
	Deficient	Intermediate	Normal	Total							
Deficient	9	30	19	58							
Intermediate	0	37	120	157							
Normal	0	20	1795	1815							
Total	9	87 1934		2030							
Venous*: Male											
	Deficient	Total									
Deficient	205	34	34								
Normal	0	214	44	2144							
Total	205	21	78	2383							
Venous*: Female											
	Deficient	Intermediate	Normal	Total							
Deficient	57	111	7	175							
Intermediate	0	96	125	221							
Normal	0	23	2042	2065							
Total	57	230	2174	2461							

^{*} Including contrived specimens

457

458

459

460

461

Table 5. Performance indicators applying the 6.0 U/g Hb threshold on the STANDARD G6PD Test for deficient and intermediate females with G6PD activity levels between 0% and 40%, 50%, 60%, 65%, and 70% for capillary specimens.

	% G6PD activity (reference assay)							
	≤ 70%	≤ 65%	≤ 60%	≤ 50%	≤ 40%			
Sensitivity (95% CI)	79.2	84.6	88.1	92.3	100.0			
	(69.7 - 86.8)	(74.7 - 91.8)	(77.8 - 94.7)	(79.1–98.4)	(83.9–100.0)			
Number of false normals	20	12	8	3	0			
Negative predictive power (95% CI)	98.9 (98.3–99.3)	99.3 (98.8–99.7)	99.6 (99.1–99.8)	99.8 (99.5–100.0)	100.0 (99.8–100.0)			

463

464

References

- 1. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. *Blood*. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944
- Luzzatto L, Arese P. Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. N Engl J Med.
 2018;378(1):60-71. doi:10.1056/nejmra1708111
- 471 3. Aydemir D, Dağlıoğlu G, Candevir A, et al. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. *Nucleosides Nucleotides Nucleic Acids*. 2021;40(5):505-517. doi:10.1080/15257770.2021.1897457
- 47. Elalfy M, Adly A, Eltonbary K, et al. Management of children with glucose-6-phosphate dehydrogenase deficiency presenting with acute haemolytic crisis during the SARs-COV-2 pandemic. *Vox Sang.* 2022;117(1):80-86. doi:10.1111/vox.13123
- 5. Dean L, Kane M. *Rasburicase Therapy and G6PD and CYB5R Genotype*. National Center for Biotechnology Information (US); 2020. Accessed May 13, 2022.
- https://www.ncbi.nlm.nih.gov/books/NBK562585/
- 480 6. Chu CS, Hwang J. Tafenoquine: a toxicity overview. *Expert Opin Drug Saf.* 2021;20(3):349-362.
 481 doi:10.1080/14740338.2021.1859476
- 7. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. *Malar J*. 2018;17(1):101. doi:10.1186/s12936-018-2248-y
- 484 8. Cunningham AD, Hwang S, Mochly-Rosen D. G6PD deficiency and the need for a novel treatment to prevent kernicterus. *Clin Perinatol*. 2016;43(2):341-354. doi:10.1016/j.clp.2016.01.010
- 486
 487
 488
 489
 480
 480
 480
 481
 482
 483
 484
 484
 485
 486
 486
 487
 488
 488
 489
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
- 489 10. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM. Addressing the burden of neonatal
 490 hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency.
 491 Acta Paediatr Oslo Nor 1992. 2014;103(11):1102-1109. doi:10.1111/apa.12735
- 492 11. Genzen JR, Nwosu A, Long T, Murphy H, Alter DN. An International Survey of Glucose-6 493 Phosphate Dehydrogenase Laboratory Reporting Practices. *Arch Pathol Lab Med.* Published online
 494 January 28, 2022. doi:10.5858/arpa.2021-0276-CP
- 495 12. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis | PLOS Medicine. Accessed May 13, 2022.
 497 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003084
- 498 13. Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-Care Testing
 499 for G6PD Deficiency: Opportunities for Screening. *Int J Neonatal Screen*. 2018;4(4):34.
 500 doi:10.3390/ijns4040034
- 501 14. World Health Organization. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. Published online 2018. Licence: CC BY-NC-SA 3.0 IGO.


- 503 15. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase
- deficiency testing: Divergent policies and practices in malaria endemic countries. *PLoS Negl Trop*
- 505 Dis. 2018;12(4):e0006230. doi:10.1371/journal.pntd.0006230
- 16. Ley B, Satyagraha AW, Rahmat H, et al. Performance of the Access Bio/CareStart rapid diagnostic
- 507 test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and
- 508 meta-analysis. *PLOS Med*. 2019;16(12):e1002992. doi:10.1371/journal.pmed.1002992
- 509 17. LaRue N, Kahn M, Murray M, et al. Comparison of Quantitative and Qualitative Tests for Glucose-6-
- Phosphate Dehydrogenase Deficiency. *Am J Trop Med Hyg.* 2014;91(4):854-861.
- 511 doi:10.4269/ajtmh.14-0194
- 512 18. Osorio L, Carter N, Arthur P, et al. Performance of BinaxNOW G6PD deficiency point-of-care
- diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92(1):22-27.
- 514 doi:10.4269/ajtmh.14-0298
- 515 19. Pal S, Bansil P, Bancone G, et al. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate
- 516 Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase
- 517 Deficiency Closer to the Patient. *Am J Trop Med Hyg.* 2019;100(1):213-221. doi:10.4269/ajtmh.18-
- 518 0612
- 20. Zobrist S, Brito M, Garbin E, et al. Evaluation of a point-of-care diagnostic to identify glucose-6-
- 520 phosphate dehydrogenase deficiency in Brazil. *PLoS Negl Trop Dis.* 2021:15(8):e0009649.
- 521 doi:10.1371/journal.pntd.0009649
- 522 21. Alam MS, Kibria MG, Jahan N, et al. Field evaluation of quantitative point of care diagnostics to
- measure glucose-6-phosphate dehydrogenase activity. *PLoS ONE*. 2018;13(11):e0206331.
- 524 doi:10.1371/journal.pone.0206331
- 525 22. Pal S, Myburgh J, Bansil P, et al. Reference and point-of-care testing for G6PD deficiency: Blood
- disorder interference, contrived specimens, and fingerstick equivalence and precision. *PLoS ONE*.
- 527 2021;16(9):e0257560. doi:10.1371/journal.pone.0257560
- 528 23. Roper DR, De la Salle B, Soni V, Fletcher K, Green JA. Abrogation of red blood cell G6PD enzyme
- activity through Heat treatment: development of survey material for the UK NEQAS G6PD scheme.
- 530 Int J Lab Hematol. 2017;39(3):308-316. doi:10.1111/ijlh.12627
- 531 24. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of
- 532 Plasmodium vivax Malaria. *N Engl J Med*. 2019;380(3):215-228. doi:10.1056/NEJMoa1710775
- 533 25. Calvaresi EC, Genzen JR. Evaluating Percentage-Based Reporting of Glucose-6-Phosphate
- Dehydrogenase (G6PD) Enzymatic Activity. *Am J Clin Pathol*. 2020;154(2):248-254.
- 535 doi:10.1093/ajcp/aqaa040
- 536 26. Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD
- 537 diagnostics: a review. *Malar J.* 2017;16(1):361. doi:10.1186/s12936-017-2017-3
- 538 27. Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination
- of malaria: recommendations for evaluation of G6PD tests. *Malar J.* 2013;12(1):391.
- 540 doi:10.1186/1475-2875-12-391


- 541 28. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and
- Assessment of Severity. World Health Organization; 2011. Accessed March 15, 2021.
- 543 https://www.who.int/vmnis/indicators/haemoglobin.pdf
- 544 29. Pfeffer DA, Ley B, Howes RE, et al. Quantification of glucose-6-phosphate dehydrogenase activity
- by spectrophotometry: A systematic review and meta-analysis. *PLoS Med.* 2020;17(5):e1003084.
- 546 doi:10.1371/journal.pmed.1003084
- 30. Ley B, Winasti Satyagraha A, Kibria MG, et al. Repeatability and reproducibility of a handheld
- quantitative G6PD diagnostic. PLoS Negl Trop Dis. 2022;16(2):e0010174.
- 549 doi:10.1371/journal.pntd.0010174
- 31. Fu C, Luo S, Li Q, et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in
- Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci
- 552 Rep. 2018;8(1):833. doi:10.1038/s41598-017-17667-6
- 32. Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader D. Glucose-6-phosphate dehydrogenase
- deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. *J Pediatr*.
- 555 2012;161(2):191-6.e1. doi:10.1016/j.jpeds.2012.02.018
- 556 33. Doherty AN, Kring EA, Posey YF, Maisels MJ. Glucose-6-phosphate dehydrogenase activity levels
- 557 in white newborn infants. J Pediatr. 2014;164(6):1416-1420. doi:10.1016/j.jpeds.2014.02.029
- 558 34. Kaplan M, Abramov A. Neonatal Hyperbilirubinemia Associated With Glucose-6-Phosphate
- 559 Dehydrogenase Deficiency in Sephardic-Jewish Neonates: Incidence, Severity, and the Effect of
- Phototherapy. *Pediatrics*. 1992;90(3):401-405. doi:10.1542/peds.90.3.401
- 35. Bancone G, Gilder ME, Win E, et al. Quantitative G6PD point-of-care test can be used reliably on
- cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a
- 563 mixed method study. *medRxiv*. doi:10.1101/2022.07.03.22277173
- 36. Ley B, Alam MS, Satyagraha AW, et al. Variation in Glucose-6-Phosphate Dehydrogenase activity
- following acute malaria. *PLoS Negl Trop Dis.* 2022;16(5):e0010406.
- 566 doi:10.1371/journal.pntd.0010406
- 567 37. Milligan R, Daher A, Villanueva G, Bergman H, Graves PM. Primaquine alternative dosing
- schedules for preventing malaria relapse in people with Plasmodium vivax. Cochrane Database Syst
- 569 Rev. 2020;8:CD012656. doi:10.1002/14651858.CD012656.pub3
- 570 38. Chu CS, Bancone G, Kelley M, et al. Optimizing G6PD testing for Plasmodium vivax case
- 571 management and beyond: why sex, counseling, and community engagement matter. Wellcome Open
- 572 Res. 2020;5:21. doi:10.12688/wellcomeopenres.15700.2
- 573 39. Taylor WRJ, Thriemer K, Seidlein L von, et al. Short-course primaquine for the radical cure of
- Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *The*
- 575 Lancet. 2019;394(10202):929-938. doi:10.1016/S0140-6736(19)31285-1
- 576 40. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus Primaquine to Prevent Relapse
- 577 of Plasmodium vivax Malaria. N Engl J Med. 2019;380(3):229-241. doi:10.1056/NEJMoa1802537

578 41. Gerth-Guyette E, Adissu W, Brito M, et al. Usability of a point-of-care diagnostic to identify glucose-579 6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and 580 results interpretation. *Malar J*. 2021;20(1):307. doi:10.1186/s12936-021-03803-1

- 42. Aung YN, Tun STT, Vanisaveth V, Chindavongsa K, Kanya L. Cost-effectiveness analysis of G6PD diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study. *PloS One*. 2022;17(4):e0267193. doi:10.1371/journal.pone.0267193
- 43. Brito-Sousa JD, Peixoto HM, Devine A, et al. Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis. *PLoS Negl Trop Dis*.
 2022;16(3):e0010325. doi:10.1371/journal.pntd.0010325
- 44. Ganapathi M, Campbell P, Ofori K, Aggarwal V, Francis RO, Kratz A. Impact of pre-emptive rapid
 testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a
 tertiary care centre: A retrospective study. *Br J Clin Pharmacol*. Published online April 14, 2022.
 doi:10.1111/bcp.15353
- 591 45. Domingo GJ, Advani N, Satyagraha AW, et al. Addressing the gender-knowledge gap in glucose-6-592 phosphate dehydrogenase deficiency: challenges and opportunities. *Int Health*. 2019;11(1):7-14. 593 doi:10.1093/inthealth/ihy060
- 46. Alam MS, Kibria MG, Jahan N, Price RN, Ley B. Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. *BMC Res Notes*.
 2018;11(1):855. doi:10.1186/s13104-018-3964-7
- 597 47. Engel N, Ghergu C, Matin MA, et al. Implementing radical cure diagnostics for malaria: user 598 perspectives on G6PD testing in Bangladesh. *Malar J*. 2021;20(1):217. doi:10.1186/s12936-021-599 03743-w

Figure 1. Site-specific variation in G6PD activity among normal males on fresh capillary and venous specimens on A) the reference assay, and B) the STANDARD G6PD Test.*





^{*} The UK study, which included newborns and samples with blood disorders, and the Thailand study, which was conducted on frozen samples, are not included in Figure 1.






Figure 2. G6PD activity classification of the STANDARD G6PD and reference assays for A) males and B) females. G6PD status classification measured by the STANDARD G6PD test is shown on the X-axis, for capillary (grey) and venous (black) specimens, respectively. Results are plotted by the reference G6PD percent activity (Y-axis). Shaded areas correspond to true G6PD normal (green), intermediate (yellow), and deficient (red) status classifications on the reference assay.


Figure 3. Participant eligibility and outcomes for radical cure treatment options based on the results of the STANDARD G6PD Test on capillary specimens. Panels A and B represent eligibility and outcomes for daily primaquine regimen. Panels C and D represent eligibility and outcomes for tafenoquine and daily primaquine, with those who are considered ineligible for tafenoquine then considered for primaquine eligibility.






Treatment Algorithm 2: Tafenoquine and primaquine eligibility*


C. STANDARD G6PD Test result and corresponding treatment eligibility








Abbreviations: G6PD, glucose-6-phosphate-dehydrogenase; PQ, Primaquine; Hb, Hemoglobin; TQ, Tafenoquine


* No other treatment eligibility criteria (e.g., age, anemia status, pregnancy status) were considered as part of the calculation.














Supplementary Figure 4. Distribution of false normal capillary results, by study.*




^{*} Red shaded areas correspond to deficient ($\le 30\%$) reference assay values, and yellow shaded areas correspond to intermediate (30-70%) reference assay values, with darker shading at lower percent activity.



A) Capillary





Supplementary Figure 5. Regression analysis of STANDARD G6PD Test total hemoglobin measurement on A) capillary specimens, and B) venous specimens compared to complete blood count

B) Venous

